Kazia Therapeutics Limited (KZIA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KZIA POWR Grades
- KZIA scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.45% of US stocks.
- The strongest trend for KZIA is in Value, which has been heading down over the past 58 days.
- KZIA ranks lowest in Momentum; there it ranks in the 3rd percentile.
KZIA Stock Summary
- For KZIA, its debt to operating expenses ratio is greater than that reported by only 0.48% of US equities we're observing.
- With a price/sales ratio of 809.7, KAZIA THERAPEUTICS LTD has a higher such ratio than 99.49% of stocks in our set.
- As for revenue growth, note that KZIA's revenue has grown -97.72% over the past 12 months; that beats the revenue growth of just 0.84% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to KAZIA THERAPEUTICS LTD are CNCE, ABUS, MGNX, HGEN, and AUTL.
- KZIA's SEC filings can be seen here. And to visit KAZIA THERAPEUTICS LTD's official web site, go to www.kaziatherapeutics.com.
KZIA Stock Price Chart Interactive Chart >
KZIA Price/Volume Stats
| Current price | $1.00 | 52-week high | $8.61 |
| Prev. close | $1.01 | 52-week low | $0.50 |
| Day low | $0.97 | Volume | 32,100 |
| Day high | $1.04 | Avg. volume | 104,019 |
| 50-day MA | $0.70 | Dividend yield | N/A |
| 200-day MA | $2.73 | Market Cap | 13.88M |
Kazia Therapeutics Limited (KZIA) Company Bio
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Latest KZIA News From Around the Web
Below are the latest news stories about KAZIA THERAPEUTICS LTD that investors may wish to consider to help them evaluate KZIA as an investment opportunity.
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More SharesThose following along with Kazia Therapeutics Limited ( ASX:KZA ) will no doubt be intrigued by the recent purchase of... |
Kazia Therapeutics CEO talks $4.5 million capital raiseKazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to profes... |
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMSKazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors in Australia, at a price of A$0.11 per share. The placement will raise A$4.5 million (exclusive of costs). |
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo TherapiesLONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR inhibitor) in solid tumors. The collaboration plans to build on previously conducted research, including the potential use of paxalisib as an immune modulator in solid tumors. |
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILINGKazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to explore novel uses of paxalisib in solid tumours. |
KZIA Price Returns
| 1-mo | 85.08% |
| 3-mo | 10.85% |
| 6-mo | -47.92% |
| 1-year | -84.03% |
| 3-year | -76.30% |
| 5-year | -78.45% |
| YTD | 62.63% |
| 2022 | -92.70% |
| 2021 | -2.55% |
| 2020 | 99.08% |
| 2019 | 78.60% |
| 2018 | -23.58% |
Continue Researching KZIA
Want to see what other sources are saying about Kazia Therapeutics Ltd's financials and stock price? Try the links below:Kazia Therapeutics Ltd (KZIA) Stock Price | Nasdaq
Kazia Therapeutics Ltd (KZIA) Stock Quote, History and News - Yahoo Finance
Kazia Therapeutics Ltd (KZIA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...